Logo image
Effect of depemokimab on asthma control and clinical outcomes: a systematic review and meta-analysis of randomized controlled trials
Journal article   Peer reviewed

Effect of depemokimab on asthma control and clinical outcomes: a systematic review and meta-analysis of randomized controlled trials

Shun Nakahara, Maria Júlia Hallack Moura, Sumeyye K Cengiz, Manoel F Filho and Jafar Aljazeeri
Expert review of respiratory medicine, Forthcoming
13 Jun 2026
PMID: 42268259

Abstract

meta-analysis rhinosinusitis depemokimab eosinophilic asthma Asthma
Patients with eosinophilic asthma are at increased risk of poor asthma control despite optimized standard therapy. Depemokimab, a novel long-acting anti-interleukin-5 monoclonal antibody, has shown efficacy in reducing exacerbations; however, its effects across clinical outcomes have not been comprehensively synthesized. PubMed, Embase, Cochrane databases, and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) comparing depemokimab with placebo. Outcomes included Asthma Control Questionnaire-5 (ACQ-5), asthma exacerbation rate, quality of life assessed by St. George's Respiratory Questionnaire (SGRQ), and adverse events. Results were reported as mean differences (MDs) or incidence rate ratios (IRRs) with 95% confidence intervals (CIs), and heterogeneity was assessed using the I statistic. Four RCTs (  = 954) were included. Depemokimab did not significantly improve ACQ-5 (MD -0.30; 95% CI -0.92 to 0.32; I  = 73.6%;  = 0.23), but reduced exacerbation rates (IRR 0.47; 95% CI 0.36 to 0.59; I  = 0%;  < 0.001) and modestly improved SGRQ scores without reaching the MCID (MD -2.80; 95% CI -5.38 to -0.23; I  = 0.0%;  = 0.033). Safety was comparable to placebo. Depemokimab reduced exacerbations and had a comparable safety profile, but did not improve symptom control or achieve the MCID for health-related quality-of-life. The study protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration number CRD420261282685).

Metrics

1 Record Views

Details

Logo image